Initial molecular characterization of the primary tumor demonstrated wild-type status for both RAS and BRAF, preserved dihydropyrimidine dehydrogenase (DPD) activity, and a microsatellite stable (MSS) phenotype. The gene discussed is BRAF; the disease is neoplasm.